Trial Profile

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etidaligide (Primary) ; Carboplatin; Paclitaxel
Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms DRIIV-1b
Sponsors Valerio Therapeutics

Most Recent Events

09 Nov 2020 Status changed from recruiting to active, no longer recruiting, according to an Onxeo SA media release.
09 Nov 2020 Interim results published in Onxeo SA Media Release.
09 Nov 2020 According to an Onxeo SA media release, it announced the completion of enrollment and the last patient was treated.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com